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hospitalised patients with HIV-TB co-
infection
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and Keertan Dheda1,2*†
Abstract
Background: Urine LAM testing has been approved by the WHO for use in hospitalised patients with advanced
immunosuppression. However, sensitivity remains suboptimal. We therefore examined the incremental diagnostic
sensitivity of early morning urine (EMU) versus random urine sampling using the Determine® lateral flow
lipoarabinomannan assay (LF-LAM) in HIV-TB co-infected patients.
Methods: Consenting HIV-infected inpatients, screened as part of a larger prospective randomized controlled trial,
that were treated for TB, and could donate matched random and EMU samples were included. Thus paired sample
were collected from the same patient, LF-LAM was graded using the pre-January 2014, with grade 1 and 2
manufacturer-designated cut-points (the latter designated grade 1 after January 2014). Single sputum Xpert-MTB/
RIF and/or TB culture positivity served as the reference standard (definite TB). Those treated for TB but not meeting
this standard were designated probable TB.
Results: 123 HIV-infected patients commenced anti-TB treatment and provided matched random and EMU
samples. 33% (41/123) and 67% (82/123) had definite and probable TB, respectively. Amongst those with definite TB
LF-LAM sensitivity (95%CI), using the grade 2 cut-point, increased from 12% (5–24; 5/43) to 39% (26–54; 16/41) with
random versus EMU, respectively (p = 0.005). Similarly, amongst probable TB, LF-LAM sensitivity increased from 10%
(5–17; 8/83) to 24% (16–34; 20/82) (p = 0.001). LF-LAM specificity was not determined.
Conclusion: This proof of concept study indicates that EMU could improve the sensitivity of LF-LAM in hospitalised
TB-HIV co-infected patients. These data have implications for clinical practice.
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Background
The HIV pandemic has fueled a resurgence of tubercu-
losis (TB), which is the leading cause of death in HIV-
infected persons in sub-Saharan Africa [1]. Rapid initi-
ation of TB treatment may reduce mortality in these vul-
nerable patients making early diagnosis an imperative [2,
3]. However, there are several hurdles to diagnosis in-
cluding lack of sputum production, sputum bacillary
concentrations below the detection threshold of same
day diagnostic tests, and atypical clinical presentation.
This is further aggravated by the high frequency of
extra-pulmonary (EPTB) and disseminated forms of TB
with advancing immunosuppression.
Thus, there is a urgent need for new, accurate, and
rapid non-sputum-based TB diagnostics that have high
sensitivity in patients with HIV/TB co-infection with
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advanced immunosuppression [4]. The Alere Determine®-
TB LAM Ag lateral flow assay (Alere, USA; referred to as
LF-LAM) that detects urine lipoarabinomannan, a M.tb
cell wall-associated glycolipid, is the most promising and
only commercially available option [5]. LAM is a point-of-
care test that is simple to use, requires no instruments,
provides a result in just 25 min, and is low cost (<US
$3.50 per test). Importantly, it is non-sputum based and is
therefore useful for patients who cannot produce sputum
[6]. A LAM-guided treatment strategy has recently been
shown to reduce mortality in hospitalized HIV-infected
inpatients with suspected TB [1]. However, LF-LAM sen-
sitivity remains sub-optimal (40–60% in HIV co-infected
patients with a CD4 count < 100 cells/ml) [7]. Thus, strat-
egies to improve sensitivity are urgently required.
Early morning urine (EMU) is accepted as a useful
method for improving the concentrations of a number
of antigens and analytes found in human urine [4, 8].
The strategy has been shown to improve the yield of
urine culture for TB diagnosis [9]. Thus, we hypothe-
sised that point-of-proof concept study by collecting
early morning urine, compared to a random spot urine
specimen, may be a simple, low cost, and effective strat-
egy to improve the sensitivity of LAM in hospitalised
HIV-infected patients with suspected TB.
Methods
The study population comprised HIV-infected adults
(>18 yrs.) prospectively recruited between June 2012 and
February 2014 from four hospitals: New Somerset,
Victoria, Mitchells Plain and Groote Schuur Hospital, in
Cape Town, South Africa. HIV-infected patients were re-
ferred for screening by emergency room or hospital doc-
tors if they were HIV-infected, older than 18 years, and
suspected of having TB. They were enrolled if they: 1.
provided informed consent, 2. were able to provide both
random and early morning urine sample, and 3. initiated
anti-TB treatment either based on clinical and radio-
logical findings, or sputum-based smear or Xpert MTB/
RIF positivity. For reasons of practicality (staff only
worked during office hours on week days) and ethical
conduct of the study (treatment in severely ill patients
cannot be delayed) patients had invariably started anti-
TB treatment. Patients were excluded if: 1. all rapid
sputum-based TB diagnostics were negative and no
treatment was initiated based on clinical and radiological
findings, and 2. they were unable to provide matched
random and early morning urine samples.
All patients enrolled provided written informed con-
sent and had basic clinical information collected, includ-
ing demographics, past history of TB, presenting
symptoms and vital signs. The study was approved by
the University of Cape Town Human Research Ethics
Committee (HREC REF 720/2013).
Tuberculosis case definitions
The reference standard for TB was single sputum sam-
ple positive liquid TB culture and/or Xpert MTB/RIF
assay. Definite TB required a clinical presentation com-
patible with TB, initiation of anti-TB treatment by the
attending clinician, with any sample M. tb culture or
Xpert MTB/RIF positive. Probable TB required a
clinical-radiological picture compatible with TB, and ini-
tiation of anti-TB treatment by the attending clinician
but M. tb culture and/or Xpert MTB/RIF were negative.
As specificity was not an objective of this study non-TB
patients were not recruited. However, specificity is re-
ported in the related randomized controlled trial [1].
TB diagnostic sampling and testing
Consultant-led hospital-based clinicians unassociated
with the study determined the timing and extent of TB
diagnostic work-up, and the commencement of anti-TB
treatment. Routine hospital practice included the collec-
tion, where possible, of two sputum samples in patients
able to expectorate. Sputum-based reference testing was
performed on admission and prior to treatment (this
was either on the same-day or prior to LF-LAM testing).
The local reference laboratory processed all clinical
specimens collected for TB diagnosis. The Xpert MTB/
RIF assay and/or culture, using MGIT 960 liquid culture
system (BD Diagnostics, USA), was performed on spu-
tum samples and Xpert MTB/RIF assay was performed
according to manufacturer’s instructions [10].
Urine sampling and LF-LAM methodology
Paired samples of EMU and random urine were col-
lected from each patient. All patients were required to
give a random urine sample (30 ml) collected in a sterile
container at enrolment; a random catheter sample was
collected if a urinary catheter was in-situ in bedbound
patients. The patients were also given a sterile container
for collecting the first EMU - first void urine of the day
between 05 h00 and 07 h00. The LF-LAM was done on
random samples at the bedside and additionally on
matched fresh bedside EMU samples the following day.
All samples were tested using the Alere Determine®-TB
LAM Ag lateral flow assay (Alere, USA).
Briefly, 60 μl of urine was pipetted onto the lateral
flow strip loading bay (pipettes were provided with the
strips). After 25–35 min, the LF-LAM was read by two
independent readers blinded to the reference test results,
via the following procedure: test validity was confirmed
by identifying the presence of a band in the positive con-
trol window; the intensity of the colour band (if any) in
the patient window was read by comparison with the
pre-January 2014 manufacturer-provided visual reference
scale card (graded 0–5 depending on band intensity).
Using the manufacturer-recommended grade 2 cut-point
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(designated grade 1 post January 2014), a band of visual
intensity ≥ grade 2 in the patient window was classified
as a ‘positive’ test, while the complete absence of a band
(grade 0) and faint band (grade 1) was classified as a
‘negative’ test. The test was reported as invalid either if
no control band was identified in the patient window or
if a broken/incomplete band was seen in the patient
window. Invalid tests were repeated once but thereafter
LF-LAM was considered to have failed. Each test was
confirmed by a second reader.
Statistical analysis
Descriptive statistics are used for baseline demographic
and clinical characteristics. Diagnostic accuracy mea-
sures included only sensitivity with the 95% confidence
interval. McNemar’s test was used to compare sensitivity
proportion between random and EMU samples. Predic-
tors of an increased LF-LAM grade between random
and EMU was performed, using multivariate linear re-
gression. Data was analysed, using STATA software, ver-
sion 11. The STARD criteria for all reporting and
analysis were used [11].
Results
184 patients were enrolled but 61 patients were excluded
as they had all sputum-based TB diagnostics negative
and were not given treatment (n = 52), or were unable to
provide a urine sample at the time of enrolment (n = 9;
Fig. 1). The median age (IQR) was 36 (31–41) years and
58% of patients were female. The majority of patients
had advanced immunosuppression with a median (IQR)
CD4 of 88 (36-209) cells/l (Additional file 1).
LF-LAM sensitivity in spot versus EMU
Patient characteristics stratified by LAM strip results are
shown in Table 1. 34% (41/123) of patients had culture/
Xpert MTB/RIF positive definite TB from sputum, while
66% (83/123) had probable-TB with other diagnostic fea-
tures suggestive of TB, including clinical findings, radio-
logical evidence suggestive of TB (chest x-ray,
ultrasound). No other biological samples were tested in
this cohort. Table 1 shows the sensitivity of LF-LAM in
random versus EMU samples for definite- and probable-
TB groups. Overall (definite- and probable-TB com-
bined), the sensitivity (95% CI) of EMU improved
from 10% (6–17) to 30% (22–38) with EMU (p < 0.001)
using the grade 2 cut- point. Limiting the analysis to
only patients with definite TB, LF-LAM sensitivity,
using the grade 2 cut-point, increased from 12% (5–
24) to 39% (26–54), in random versus EMU samples,
respectively (p = 0.005); amongst probable TB, LF-
LAM sensitivity increased from 10% (5–17) to 24%
(16–34) (p = 0.001).
The data were stratified by CD4 counts (>200, <200,
<100 and <50 cell/mm3) to determine whether, as in
other studies, CD4 cell count played a significant role
in LF-LAM grade (Fig. 2). Notably There was a
Fig. 1 Flowchart showing study population, Xpert/culture status and diagnostic groups
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significant increase in sensitivity for definite TB in the
CD4 < 200 between random and EMU specimen sensi-
tivity for individual CD4 strata (p = 0.01).
Predictors of increased LF-LAM positivity between spot
and EMU
None of age, Xpert MTB/RIF/liquid TB culture posi-
tivity, or prior initiation of anti-TB treatment within
7 days were significant predictors of an increasing
LF-LAM grade between spot and EMU specimens
(Table 2).
Discussion
The WHO has recently endorsed the use of LF-
LAM testing for hospitalised HIV-infected patients
with suspected TB [7]. In addition, we recently
published a multicentre RCT showing that a LAM-
guided early TB treatment initiation strategy reduced
all-cause mortality amongst this vulnerable patient
group [1]. However, test sensitivity remains sub-
optimal and simple strategies that could improve test
sensitivity are necessary. This proof-of-principle study
suggests that using EMU can increase the sensitivity of
LF-LAM testing compared to random spot urine sam-
pling. This could further improve the utility of LF-LAM
for hospitalised HIV infected patients with advanced im-
munosuppression and possible TB.
A number of strategies have already been published or
are being examined to improve the sensitivity of LAM.
These include high avidity monoclonal LAM antibodies
or aptamer technologies that could improve both sensi-
tivity and specificity [5], concentrating urine samples to
improve sensitivity using centrifugation and/or molecu-
lar weight exclusion filtration, and heating to dissociate
antigen and antibody [5]. These approaches improve
sensitivity but has not been implemented in clinical tri-
als. Designing a new LAM assay will take several years
of development, whilst other approaches will add to cost
and resource requirements. Therefore, a natural low cost
method for antigen concentration, namely EMU sampling
may be a practical and ease-to –implement strategy. A re-
cent study showed no improvement in LF-LAM sensitivity
from a two urine sample strategy. However, EMU sam-
pling was performed up to seven days after the 1st spot
urine was collected, and the timing of morning sampling
was not stipulated [12]. These methodological shortcom-
ings may have offset the benefit of early morning sam-
pling. Further studies are now required to confirm our
findings, consider any impact on specificity, and most im-
portantly to assess the impact on patient-important
outcomes.
Our study did not find any factors that were associated
with an increase in EMU LAM concentration (as mea-
sured by the change in LF-LAM grade). Factors known
to affect LAM concentration, such as CD4 cell count,
age and culture/Xpert MTB/RIF status were not associ-
ated with an increased LF-LAM grade [13]. This seems
biologically plausible given that these factors would
likely be unchanged between spot and EMU sampling
time-points. It is likely that physiological factors such as
blood pressure, hydration status, and consequent glom-
erular filtration rates are more important determinants
of increased EMU LAM concentration. Interestingly, we
did not find that anti-TB treatment initiated prior to
spot and EMU, or between spot and EMU testing, was
associated with increased EMU LAM. This does not
support the “treat-to-test” hypothesis, which suggests
that the concentration of bacillary antigens such as
LAM may increase immediately following the initi-
ation of anti-TB treatment due to death and metabol-
ism of bacilli [14]. Perhaps the effect of treatment on
systemic antigenemia is not as large as hypothesized
and other factors such as complexing of LAM to
serum proteins have a larger influence on urinary
LAM concentrations.
Table 1 Overall sensitivity of the urine LAM using random
versus EMU samples, and stratified by diagnostic category and
preceding anti-TB treatment
Sensitivity
95% (CI)
Manufacturer
recommended LF-LAM
positive cut point (grade 2)
P-value
Random Urine
%, 95% CI, n/N
Early Morn. Urine
%, 95% CI, n/N
Definite- TB only 12
(5–24)
(5/41)
39
(26–54)
(16/41)
0.005
Probable TB only 9.6
(5–17)
8/82
24
(16–34)
20/82
0.001
Definite and
Probable
TB combined
10
(6–17)
(13/123)
30
(22–38)
(36/123)
<0.001
No TB Rx prior 11
(4–28)
(3/27)
31
(17–50)
(8/26)
0.05
TB Rx prior
<7 days
10
(2–40)
(1/10)
56
(27–81)
(5/9)
0.04
No TB Rx prior 15
(8–27)
(8/52
25
(15–38)
(13/52)
0.1
TB Rx prior
< 7 day
0
(0–11)
(0/30)
23
(12–41)
(7/30)
0.003
No TB Rx prior 14
(8–23)
(11/79)
30
(18–38)
(21/78)
0.03
TB Rx prior
< 7 days
2
(0–12)
(1/42)
30
(18–45)
(12/40)
<0.001
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Our study had several limitations. The sample size
was small and we did not collect sufficient co-variate
physiological data to adequately understand which pa-
tients are likely to have an increase in urine LAM
with EMU sampling. However, resource constraints
limited sample size. In many cases those with extra-
pulmonary-TB had diagnosis made based on clinical,
radiological findings, and did not have microbiological
samples harvested from the site of presumed disease
this may have led to a misclassification biased. The
study did not examine the effect of EMU on test spe-
cificity and it is possible that improved sensitivity
comes at the expense of decreased specificity (EMU
may have increased the risk of false positive signals
from bacterial or fungal cross contamination though
this would seem unlikely). However, the primary aim of
this study was to demonstrate proof-of-concept that EMU
could improve diagnostic sensitivity; specificity of LAM is
reported in the related RCT [1]. The study highlights the
diagnostic implications of the timing of sample collection
with EMU testing significantly improving LF-LAM sensi-
tivity in hospitalised TB/HIV co-infected patients. Larger
studies are now required to confirm our findings and
importantly, to determine if the incremental sensitiv-
ity can translate to impact on patient important out-
comes, or if the delay in time required between spot
and EMU sampling negates the benefits of testing. In
the meanwhile, it would seem sensible to collect an
EMU sample for LAM testing provided treatment ini-
tiation will not be delayed.
Conclusion
EMU could improve the sensitivity of LF-LAM in hospi-
talised TB-HIV co-infected patients. These data have im-
plications for clinical practice.
Table 2 Multivariate predictors of increasing urine LF-LAM test grade when using random versus EMU specimens
P-value Adjusted
Odds Ratio
Lower 95% CI Upper 95% CI
No = 61
Age, years 0.32 0.967 0.906 1.03
CD4 cell count, cells/mm3 0.92 1.000 0.996 1.005
TB culture/Xpert positive (pos/neg) 0.15 2.201 0.760 6.379
TB treatment < 7 days 0.41 1.59 0.53 4.81
Fig. 2 Overall sensitivity of the urine LAM strip test using random versus EMU samples and stratified by CD4 count
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Abbreviation
EMU: Early morning urine; HIV: Human immunodeficiency virus;
LAM: Lipoarabinomannan; LF-LAM: Lateral flow lipoarabinomannan assay;
M.tb: Mycobacterium tuberculosis; POC: Point-of-care; WHO: World Health
Organisation
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